About Kanvas Biosciences
Kanvas Biosciences is a Healthcare company based in Ithaca (United States) founded in 2021 by Iwijn De Vlaminck and Matthew P Cheng. Imaging solutions for microbial research and infectious diseases are provided. Kanvas Biosciences has raised $24.28 million across 3 funding rounds from investors including Germin8, DCVC and Lion Capital. Kanvas Biosciences offers products and services including Spatial Mapping Platform and Live Biotherapeutics Pipeline. Its focus areas include Life Sciences, Gastroenterology, Drugs and Bowel Disorders. Its competitors include Moderna, BeiGene and Aclaris Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Kanvas Biosciences was founded in 2021 in Ithaca, United States, as a provider in the biotechnology sector. Solutions focused on imaging for microbial research and infectious diseases are developed and offered. Operations center on advancing tools for scientific applications in these areas. The company is co-founded by Iwijn De Vlaminck and Matthew P Cheng, with activities based in the United States.
- Headquarters Ithaca, United States
- Founders Iwijn De Vlaminck, Matthew P Cheng
- SectorsHealthcare
- Email••••••••
- Website kanvasbio.com
- Social LinkedIn X
- Total Equity Funding$24.28M (USD)
in 3 rounds
- InvestorsGermin8
& 8 more
Products & Services of Kanvas Biosciences
Kanvas Biosciences offers a comprehensive portfolio of products and services, including Spatial Mapping Platform and Live Biotherapeutics Pipeline.
Platform for mapping host-microbiome interactions in drug discovery.
Pipeline for microbiome-modulating treatments in health and disease.
Funding Insights of Kanvas Biosciences
Kanvas Biosciences has successfully raised a total of $24.28M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.28M
- Total Rounds 3
- First Round $11.78M
(Jun 2023)
- Investors Count 9
All 3 funding rounds of Kanvas Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
9 investors in total: 9 institutional.
Investors in Kanvas Biosciences
Kanvas Biosciences has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Germin8, DCVC and Lion Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Private equity firm focused on consumer brands | lioncapital.com | London, United Kingdom | ||
Investments are focused on innovations in women's health. | 2019 | femhealthventures.com | ||
Ki Tua Fund is focused on investing in health-focused startups. | kituafund.com | |||
Investment in hard tech for planetary health, focusing on materials science, chemistry, and biology. | pangaeaventures.com | |||
| cookellc.com | ||||
Early-stage venture capital investments are provided by Uncommon Denominator. | uncommonvc.com | New York, United States | ||
Triple Impact Capital is focused on impact-driven venture investments. | tripleimpactcapital.com | San Francisco, United States | ||
Social media conversations are tracked and analyzed for brand insights. | 2007 | germin8.com | Mumbai, India |
Investor details for Kanvas Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kanvas Biosciences
13 people are tracked at Kanvas Biosciences (9 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Iwijn De Vlaminck | Co-Founder | Leadership |
Matthew P Cheng | Co-Founder | Leadership |
Joshua Hopper | Director Of Information Technology | Leadership |
James Berleman | VP Of Discovery & Development | Leadership |
Kyle Jacoby | Vice President Of Clinical Research | Leadership |
Lee Swem | Chief Development Officer | Leadership |
Matthew Cheng | Chief Executive Officer | Leadership |
Hao Shi | Chief Technology Officer | Leadership |
Steve Kujawa | Vice President Of Business Development | Leadership |
Prateek Sehgal | Principal Scientist | Team |
Gregory Booth | Senior Principal Scientist | Team |
Jack Mintz | Associate Scientist 3 | Team |
Kellen Cao | Project Intern | Team |
Complete people profiles for Kanvas Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kanvas Biosciences
3 dated milestones of Kanvas Biosciences across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Kanvas Biosciences is founded.
- Funding First funding round of $11.8M.
- Funding Latest funding round, Series A,.
Competitors of Kanvas Biosciences
Kanvas Biosciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Aclaris Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. |
Detailed competitors of Kanvas Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kanvas Biosciences
The website of Kanvas Biosciences (kanvasbio.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 2.8% vs previous month
Top companies in Gastroenterology
3 companies that operate in the same segment as Kanvas Biosciences (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kanvas Biosciences
Complete news archive for Kanvas Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kanvas Biosciences
Kanvas Biosciences was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Kanvas Biosciences is headquartered in Ithaca, United States. It is registered at Ithaca, New York, United States.
Kanvas Biosciences is a funded company, having raised a total of $24.28M across 3 funding rounds to date. The company's 1st funding round was a Seed of $11.78M, raised on Jun 2023.
Kanvas Biosciences was founded in 2021 in Ithaca, United States, as a provider in the biotechnology sector. Solutions focused on imaging for microbial research and infectious diseases are developed and offered. Operations center on advancing tools for scientific applications in these areas. The company is co-founded by Iwijn De Vlaminck and Matthew P Cheng, with activities based in the United States.
Kanvas Biosciences's top competitors include Moderna, BeiGene and Aclaris Therapeutics.
Kanvas Biosciences offers Spatial Mapping Platform and Live Biotherapeutics Pipeline.
Kanvas Biosciences has 9 investors. Key investors include Germin8, DCVC, Lion Capital, FemHealth Ventures, and Ki Tua Fund.